<DOC>
	<DOCNO>NCT00604864</DOCNO>
	<brief_summary>Deep endometriosis associate pain believe caused inflammation . Anti TNFa prove effective treatment inflammation relate condition Crohn 's disease Endometriosis associate inflammatory response pelvis , mediate number cytokine include TNF-α . It therefore suggest infliximab , anti-TNF-α monoclonal antibody , might relieve pain affected woman .</brief_summary>
	<brief_title>Effect Anti TNFa Upon Deep Endometriosis Associated Pain</brief_title>
	<detailed_description>In pilot study , 21 woman severe endometriosis-associated pain rectovaginal nodule , least 1 cm diameter clinical examination , randomise 2 1 ratio receive intravenous infliximab ( n=14 ) placebo ( n=7 ) three month prior laparoscopic laser excision nodule . After 1 month observation period , woman receive three infusion infliximab ( 5mg/kg ) placebo course 6 week . Surgery perform 3 month later follow-up continued 6 month . The primary endpoint total pain burden ( dysmenorrhoea , deep dyspareunia non-menstrual pain ) rat daily basis patient use standard pain scale analgesic intake outcome measure . Secondary endpoint include volume endometriotic nodule assess clinically transvaginal ultrasound , amount pelvic tenderness clinical examination presence endometriotic lesion laparoscopy .</detailed_description>
	<mesh_term>Endometriosis</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>The patient ( age 1850 year ) recruit single , tertiary referral hospital Leuven University , Belgium , specialise surgical treatment severe endometriosis . All woman symptomatic scheduled surgical excision rectovaginal nodule , least 1 cm diameter , diagnose basis clinical examination time menstruation . All woman menstrual cycle occur every 25 40 day . If previously treat hormonal medication endometriosis , least 3 month must elapse must least two menstrual cycle since stop treatment . Unless woman previously sterilise , agree use doublebarrier method contraception duration study 6 month receive last infusion . The study approve Institutional Review Board Leuven University . Written , inform consent obtain study related procedure perform . Evidence chest xray previous 3 month old currently active TB , history/evidence active TB , even adequately treated Evidence serious infection ( pneumonia pyelonephritis ) previous 3 month Evidence document HIV infection , active hepatitisB C , opportunistic infection ( e.g . herpes zoster , cytomegalovirus , pneumocystis carinii , aspergillosis , histoplasmosis , mycobacteria TB ) previous 6 month Previous transplant surgery , lymphoproliferative disorder malignancy Positive cervical cytology previous 6 month Previous treatment infliximab , drug know affect TNFα level , e.g . pentoxifylline , thalidomide etanercept , human/murine recombinant product Known allergy murine product Use investigational drug within 1 month recruitment within 5 halflives investigational agent , whichever longer Any haematological biochemical abnormality routine screen . Subjects also exclude pelvic pathology transvaginal ultrasound scan ( TVS ) small uterine fibroid ( &lt; 4 cm diameter ) ovarian endometrioma endometriotic nodule .</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>deep endometriosis</keyword>
	<keyword>pelvic pain</keyword>
	<keyword>infliximab</keyword>
	<keyword>anti TNFa</keyword>
</DOC>